亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study)

T790米 奥西默替尼 医学 内科学 肺癌 临床终点 肿瘤科 临床试验 癌症 胃肠病学 腺癌 ROS1型
作者
Inger Johanne Zwicky Eide,Åslaug Helland,Simon Ekman,Anders Mellemgaard,Karin Holmskov Hansen,Saulius Cicėnas,Jussi Pekka Koivunen,Bjørn Henning Grønberg,Odd Terje Brustugun
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:143: 27-35 被引量:69
标识
DOI:10.1016/j.lungcan.2020.03.009
摘要

OBJECTIVES: In non-small cell lung cancer patients with acquired resistance to first- or second-generation EGFR-TKIs, osimertinib is approved in the presence of the T790 M resistance mutation. We assessed the efficacy of osimertinib in both T790M-positive and T790M-negative patients. MATERIALS AND METHODS: The TREM-study is an investigator-initiated, multi-centre, single-arm, phase 2 clinical trial conducted in five Northern European countries. Patients with progression on at least one previous EGFR-TKI were assigned to treatment with 80 mg of osimertinib daily until radiological progression or death. Patients were included regardless of the presence of T790 M. The primary endpoint was objective response rate (ORR). RESULTS: Of 199 included patients, 120 (60 %) were T790M-positive, 52 (26 %) were T790M-negative and 27 (14 %) had unknown T790M-status. 24 % had brain metastases and 15 % had an ECOG performance status of 2. Overall ORR was 48 % (95 % CI, 41 %-55 %), 60 % (51 %-69 %) for T790M-positive patients and 28 % (15 %-41 %) for T790M-negative patients, p < 0.001. ORR for patients with co-occurring del19 vs L858R was 61 % vs 32 %, p = 0.001. Duration of response was similar between the T790M-positive and -negative groups (11.8 vs 10.7 months, p = 0.229). Overall median progression-free survival (PFS) was 8.9 months (95 % CI, 7.4-10.5), and 10.8 vs 5.1 months for T790M-positive vs -negative patients (HR 0.62, p = 0.007). Median overall survival (OS) was 17.9 months (95 % CI, 14.4-21.3). For T790M-positive vs -negative median OS was 22.5 vs 13.4 months, (HR 0.55, p = 0.002). CONCLUSIONS: This study confirms the efficacy of osimertinib for T790M-positive patients. There was also clinically significant activity of osimertinib in a proportion of T790M-negative patients. CLINICAL TRIAL REGISTRATION: This trial is registered with ClinicalTrials.gov (NCT02504346).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
4秒前
落后的雨筠完成签到,获得积分10
5秒前
lin完成签到,获得积分10
6秒前
6秒前
BIBIYU完成签到,获得积分10
7秒前
9秒前
10秒前
汤小圆完成签到,获得积分10
11秒前
11秒前
Echo完成签到,获得积分10
11秒前
爆米花的应助被伯赏诗霜采纳,获得10
12秒前
耍酷花卷完成签到,获得积分10
12秒前
15秒前
佳1发布了新的文献求助10
17秒前
自信的寄松完成签到 ,获得积分10
18秒前
姜晔发布了新的文献求助10
18秒前
卢茵完成签到,获得积分10
20秒前
超帅的香露完成签到,获得积分10
24秒前
内向南风完成签到 ,获得积分10
25秒前
Apei完成签到 ,获得积分10
25秒前
Viiigo完成签到,获得积分10
28秒前
L8完成签到,获得积分10
30秒前
木有完成签到 ,获得积分10
32秒前
了了发布了新的文献求助10
32秒前
wangyucode完成签到,获得积分10
34秒前
34秒前
35秒前
40秒前
LSQ完成签到,获得积分10
41秒前
lemon完成签到,获得积分10
41秒前
43秒前
寒叶霖完成签到 ,获得积分10
46秒前
46秒前
阿睿完成签到,获得积分10
46秒前
FIGGIEKIO发布了新的文献求助10
46秒前
在逃板砖完成签到 ,获得积分10
46秒前
星星富柜完成签到 ,获得积分10
48秒前
茅文荣发布了新的文献求助10
51秒前
着急的水桃完成签到,获得积分10
52秒前
00hello00发布了新的文献求助10
54秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194962
求助须知:如何正确求助?哪些是违规求助? 9580711
关于积分的说明 21872442
捐赠科研通 7794663
什么是DOI,文献DOI怎么找? 3437819
关于科研通互助平台的介绍 2561143
邀请新用户注册赠送积分活动 2484511